212 related articles for article (PubMed ID: 38910268)
1. Recent Advances in CAR-T Therapy.
Ali MB
Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
[TBL] [Abstract][Full Text] [Related]
2. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
3. Advances in CAR-T-cell therapy in T-cell malignancies.
Zheng R; Zhu X; Xiao Y
J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
[TBL] [Abstract][Full Text] [Related]
4. CAR T-cell therapy: perceived need versus actual evidence.
The Lancet Oncology
Lancet Oncol; 2018 Oct; 19(10):1259. PubMed ID: 30303110
[No Abstract] [Full Text] [Related]
5. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
6. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
7. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
8. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
Fleischer LC; Spencer HT; Raikar SS
J Hematol Oncol; 2019 Dec; 12(1):141. PubMed ID: 31884955
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
10. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
11. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
12. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
Zhou D; Zhu X; Xiao Y
Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
Khvorost D; Kendall B; Jazirehi AR
Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
[TBL] [Abstract][Full Text] [Related]
14. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
16. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
Shumnalieva R; Velikova T; Monov S
Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y
Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
20. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
Li Y; Hu Z; Li Y; Wu X
Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
